Key terms
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company that focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (fampridine). The firm also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACOR news
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Apr 04
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Apr 03
5:32pm ET
Acorda Therapeutics delisted from Nasdaq
Apr 02
10:37am ET
Acorda sinks 86% after filing Chapter 11, selling assets
Apr 02
10:21am ET
Acorda Therapeutics trading resumes
Apr 02
10:16am ET
Acorda Therapeutics trading halted, volatility trading pause
Apr 02
6:13am ET
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan
Apr 01
6:36pm ET
Acorda Therapeutics, Merz sign “stalking horse” asset purchase deal for $185M
Apr 01
4:01pm ET
Acorda Therapeutics cancels Q4 earnings conference call
Jan 11
8:12am ET
Acorda regains rights to Fampyra after Biogen terminates license agreement
No recent press releases are available for ACOR
ACOR Financials
Key terms
Ad Feedback
ACOR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACOR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
